Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 7 sources · 15 days · First seen · Last updated
Sanofi EU antitrust settlement over influenza vaccine
Overview
Sanofi has reached an agreement with the European Commission to resolve an antitrust investigation into the marketing of its influenza vaccine, Efluelda. The investigation examined whether the company used misleading claims in Germany and France to suggest its product was superior to a competing vaccine, Fluad, developed by CSL Seqirus.
Under the terms of the settlement, Sanofi must cease disparaging the competitor and revise its advertising materials. The company is required to implement corrective measures in France and Germany for two years, which includes publishing online statements acknowledging the scientific evidence supporting both vaccines to ensure medical professionals can make impartial decisions.
While Sanofi avoids financial penalties through this agreement, it remains subject to significant potential fines—up to ten percent of its total annual worldwide turnover—should it fail to adhere to these legally binding commitments.
Entities
Efluelda · Sanofi · Fluad · European Commission · CSL Seqirus
Timeline
-
[BUSINESS] 7 sourcesSanofi reaches agreement with European Commission over flu vaccine messaging
Sanofi will avoid EU fines by agreeing to correct its promotional messaging regarding its flu vaccine, Efluelda, in France and Germany.
-
[BUSINESS] 7 sourcesSanofi reaches EU antitrust settlement over influenza vaccine advertising
Sanofi has agreed to EU antitrust commitments to stop disparaging a competing influenza vaccine in its advertising following investigations into misleading claims in Germany and France.
Sources
deultimominuto.net · immedicohospitalario.es · infoenn.com · lobosnews.com.ar · losmocanos.com · pulse.sn · wwwhatsnew.com